Chemistry:Meropenem
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Merrem, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | Approximately 2% |
| Elimination half-life | 1 hour |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C17H25N3O5S |
| Molar mass | 383.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Meropenem, sold under the brand name Merrem among others, is an intravenous β-lactam antibiotic used to treat a variety of bacterial infections.[1] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.[1]
Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection.[1] Serious side effects include Clostridioides difficile infection, seizures, and allergic reactions including anaphylaxis.[1] Those who are allergic to other β-lactam antibiotics are more likely to be allergic to meropenem as well.[1] Use in pregnancy appears to be safe.[1] It is in the carbapenem family of medications.[1] Meropenem usually results in bacterial death through blocking their ability to make a cell wall.[1] It is more resistant to breakdown by β-lactamase producing bacteria.[1]
Meropenem was patented in 1983.[2] It was approved for medical use in the United States in 1996.[1] It is on the World Health Organization's List of Essential Medicines.[3][4] The World Health Organization classifies meropenem as critically important for human medicine.[5]
Medical uses
The spectrum of action includes many Gram-positive and Gram-negative bacteria (including Pseudomonas) and anaerobic bacteria. The overall spectrum is similar to that of imipenem, although meropenem is more active against Enterobacteriaceae and less active against Gram-positive bacteria. It works against extended-spectrum β-lactamases, but may be more susceptible to metallo-β-lactamases.[6] Meropenem is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with hematological malignancies and cancer patients receiving anticancer drugs that suppress bone marrow formation. It is approved for complicated skin and skin structure infections, complicated intra-abdominal infections and bacterial meningitis.[citation needed][7]
In 2017, the U.S. Food and Drug Administration (FDA) granted approval for the combination of meropenem and vaborbactam to treat adults with complicated urinary tract infections.[8]
Administration
Meropenem is administered intravenously as a white crystalline powder to be dissolved in 5% monobasic potassium phosphate solution. Dosing must be adjusted for altered kidney function and for haemofiltration.[9]
As with other β-lactams antibiotics, the effectiveness of treatment depends on the amount of time during the dosing interval that the meropenem concentration is above the minimum inhibitory concentration for the bacteria causing the infection.[10] For β-lactams, including meropenem, prolonged intravenous administration is associated with lower mortality than bolus intravenous infusion in persons with whose infections are severe, or caused by bacteria that are less sensitive to meropenem, such as Pseudomonas aeruginosa.[10][11]
Side effects
The most common adverse effects are diarrhea (4.8%), nausea and vomiting (3.6%), injection-site inflammation (2.4%), headache (2.3%), rash (1.9%) and thrombophlebitis (0.9%).[12] Many of these adverse effects were observed in severely ill individuals already taking many medications including vancomycin.[13][14] Meropenem has a reduced potential for seizures in comparison with imipenem. Several cases of severe hypokalemia have been reported.[15][16]
Interactions
Meropenem rapidly reduces serum concentrations of valproic acid. As a result, people who use valproic acid for epilepsy are at increased risk of seizures during treatment with meropenem. In situations where the use of meropenem cannot be avoided, prescription of an additional anticonvulsant should be considered.[17]
Pharmacology
Mechanism of action
Meropenem is bactericidal except against Listeria monocytogenes, where it is bacteriostatic. It inhibits bacterial cell wall synthesis like other β-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by β-lactamases or cephalosporinases. In general, resistance arises due to mutations in penicillin-binding proteins, production of metallo-β-lactamases, or resistance to diffusion across the bacterial outer membrane.[12] Unlike imipenem, it is stable to dehydropeptidase-1, so can be given without cilastatin.
In 2016, a synthetic peptide-conjugated PMO (PPMO) was found to inhibit the expression of New Delhi metallo-beta-lactamase, an enzyme that many drug-resistant bacteria use to destroy carbapenems.[18][19]
Society and culture
Trade names
| Country | Name | Maker |
|---|---|---|
| India | UNOMERO | Scutonix Lifesciences, Bombay |
| India | Inzapenum | Dream India |
| Aurobindo Pharma | ||
| Penmer | Biocon | |
| Meronir | Nirlife | |
| Merowin | Strides Acrolab | |
| Aktimer | Aktimas Biopharmaceuticals | |
| Neopenem | Neomed | |
| Mexopen | Samarth life sciences | |
| Meropenia | SYZA Health Sciences LLP | |
| Ivpenem | Medicorp Pharmaceuticals | |
| Merofit | ||
| Lykapiper | Lyka Labs | |
| Winmero | Parabolic Drugs | |
| Bangladesh | ||
| Meroject | Eskayef Pharmaceuticals Ltd. | |
| Merocon | Beacon Pharmaceuticals | |
| Indonesia | Merofen | Kalbe |
| Brazil | Zylpen | Aspen Pharma |
| Japan, Korea | Meropen | |
| Australia | Merem | |
| Taiwan | Mepem | |
| Germany | Meronem | |
| Nigeria | Zironem | Lyn-Edge Pharmaceuticals |
| Ukraine[20] | Meropenem | Lekhim-Kharkiv |
| Panlaktam (Panlaktam) | "Darnytsia" | |
| Mepenam | Kyivmedpreparat | |
| Merobicide | Borshchahiv HFZ | |
| US | Meronem | AstraZeneca |
| Indonesia | Merosan | Sanbe Farma |
| Indonesia | Merobat | Interbat |
| Zwipen | ||
| Carbonem | ||
| Ronem | Opsonin Pharma, BD | |
| Neopenem | ||
| Merocon | Continental | |
| Carnem | Laderly Biotech | |
| Penro | Bosch | |
| Meroza | German Remedies | |
| Merotrol | Lupin) | |
| Meromer | Orchid Chemicals | |
| Mepenox | BioChimico | |
| Meromax | Eurofarma | |
| Ropen | Macter | |
| mirage | adwic | |
| Meropex | Apex Pharma Ltd. | |
| Merostarkyl | Hefny Pharma Group[21] |
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Meropenem". The American Society of Health-System Pharmacists. https://www.drugs.com/monograph/meropenem.html.
- ↑ (in en) Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 497. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA497.
- ↑ World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.
- ↑ Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. 2019. ISBN 9789241515528.
- ↑ AHFS Drug Information (2006 ed.). American Society of Health-System Pharmacists. 2006.
- ↑ "Meropenem". 16 September 2016. https://medlineplus.gov/druginfo/meds/a696038.html.
- ↑ "FDA approves new antibacterial drug". U.S. Food and Drug Administration (FDA) (Press release). 24 March 2020.
This article incorporates text from this source, which is in the public domain.
- ↑ "Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration". Antimicrobial Agents and Chemotherapy 54 (7): 2974–2978. July 2010. doi:10.1128/AAC.01582-09. PMID 20479205.
- ↑ 10.0 10.1 "Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis". PLOS ONE 13 (7): e0201667. 2018. doi:10.1371/journal.pone.0201667. PMID 30059536. Bibcode: 2018PLoSO..1301667Y.
- ↑ "Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials". The Lancet. Infectious Diseases 18 (1): 108–120. January 2018. doi:10.1016/S1473-3099(17)30615-1. PMID 29102324.
- ↑ 12.0 12.1 Mosby's Drug Consult 2006 (16 ed.). Mosby, Inc.. 2006.
- ↑ "Pancytopenýa and Sepsýs due to Meropenem: A Case Report". Tropical Journal of Pharmaceutical Research 12 (1). 7 March 2013. doi:10.4314/tjpr.v12i1.21. http://www.tjpr.org/vol12_no1/2013_12_1_21.pdf.
- ↑ "Meropenem side effects - from FDA reports". eHealthMe. http://www.ehealthme.com/meropenem/meropenem-side-effects.
- ↑ "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical Drug Investigation 24 (1): 61–62. 2004. doi:10.2165/00044011-200424010-00008. PMID 17516692.
- ↑ "Meropenem in critical care - uncovering the truths behind weaning failure". Journal of Anaesthesiology Clinical Pharmacology 26 (1): 99–101. 2010. doi:10.4103/0970-9185.75131. http://www.joacp.org/article.asp?issn=0970-9185;year=2010;volume=26;issue=1;spage=99;epage=101;aulast=Bharti;type=0.
- ↑ "Valproate Interaction With Carbapenems: Review and Recommendations". Hospital Pharmacy 55 (3): 181–187. June 2020. doi:10.1177/0018578719831974. PMID 32508355.
- ↑ "New molecule knocks out superbugs' immunity to antibiotics". 20 January 2017. http://newatlas.com/molecule-weakens-superbugs-immunity-antibiotics/47483.
- ↑ "Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo". The Journal of Antimicrobial Chemotherapy 72 (3): 782–790. March 2017. doi:10.1093/jac/dkw476. PMID 27999041.
- ↑ "МЕРОПЕНЕМ (MEROPENEMUM)" (in uk). Compendium. https://compendium.com.ua/uk/akt/77/739/meropenemum/.
- ↑ "Hefny Pharma Group". http://hefnypharmagroup.info/en/therapeuticAreas/Hospital-line/99/Merostarkyl-500-mg.
External links
- "Meropenem". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/rn/119478-56-7.
 |  |
